Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia
- Registration Number
- NCT03751917
- Brief Summary
The therapeutic advantage of the association of ATRA + Arsenic Trioxide is more favorable and manageable as compared to ATRA + chemotherapy. Nevertheless, at present, there is not enough information on the incidence of long-term side effects.
This study, as well as other similar studies conducted around Europe, will focus on following patients treated with this therapy on a long-term basis.
Once all studies in Europe will be concluded, all data will be analyzed together.
- Detailed Description
Considering the clear therapeutic advantage associated with ATRA+ATO combination therapy and the more favorable and overall manageable safety profile compared to ATRA+chemotherapy, the benefits of the combination in the first-line indication do appear to overweigh the risks.
However, no information regarding the actual adverse event (AE) incidence and the long-term toxicity of ATRA+ATO is available at present and therefore, as a postmarketing commitment, TEVA (the Company holding the Marketing Authorisation of Trisenox® (Arsenic trioxide)) is setting up a long-term safety cohort study of Trisenox in newly diagnosed low- to intermediate-risk APL patients retrospectively analyzing data from APL disease registries all around Europe.
As a result, this observational study is part of the retrospective PASS Study (A Post-Authorisation Long-Term Retrospective Safety Cohort Study of Arsenic Trioxide in First Line Low-to Intermediate-Risk Acute Promyelocytic Leukaemia Patients) that will use data from multinational APL disease registries in Europe. The present study will focus on Italian patients.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
- APL diagnosis based on cytological criteria and confirmed by the presence of the (15;17) translocation and/or the presence of the PML/RARA rearrangement (with the determination of the breakpoint subtype).
- Newly diagnosed low- to intermediate-risk APL (white blood cells [WBC] count ≤10x103/µL)
- First line treatment with ATRA+ATO
- Aged 18 years or above
- Signed informed consent, if applicable
- High risk APL (WBC count > 10x103/µL)
- APL relapse
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description APL patients Arsenic Trioxide The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
- Primary Outcome Measures
Name Time Method Number of grade III/IV (Common Terminology Criteria for Adverse Events (CTCAE) v4.03) adverse events of special interest (AESI). At a maximum of 5 years from study entry AESI are, among others: differentiation syndrome, creatinine, bilirubin, neurotoxicity, aspartate amino transferase/alanine amino transferase (ASAT/ALAT) ratio, haemorrhage, sepsis, QTc prolongation, cardiac events including congestive heart failure (CHF).
- Secondary Outcome Measures
Name Time Method Number of unexpected serious adverse events (SAEs). At a maximum of 5 years from study entry Including grading and relationship as documented in the study.
Number of patients developing acute myeloid leukemia (tAML). At a maximum of 5 years from study entry Number of patients developing secondary malignancies. At a maximum of 5 years from study entry Number of patients developing therapy-related myelodysplastic syndrome (tMDS). At a maximum of 5 years from study entry Number of patients who die. At a maximum of 5 years from study entry
Trial Locations
- Locations (28)
U.O.C. Oncoematologia - Istituto Oncologico Veneto Irccs, Presidio Ospedaliero S. Giacomo Apostolo
🇮🇹Castelfranco Veneto, Italy
Fondazione IRCCS Ca' Granda Osp. Maggiore Policlinico UOC Oncoematologia
🇮🇹Milano, Italy
Azienda Ospedaliera "S.Gerardo"
🇮🇹Monza, Italy
Napoli Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"
🇮🇹Naples, Italy
Ospedali Riuniti "Villa Sofia-Cervello"
🇮🇹Palermo, Italy
Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2
🇮🇹Torino, Italy
Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia
🇮🇹Roma, Italy
Dipartimento di Oncologia Ematologia 2 A.O. Citta' della Salute S. G. Battista
🇮🇹Torino, Italy
Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia
🇮🇹Vicenza, Italy
Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
🇮🇹Bari, Italy
A.O. Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - U.O. di Ematologia
🇮🇹Catanzaro, Italy
Aou Policlinico Tor Vergata - Roma - Uoc Trapianto Cellule Staminali
🇮🇹Roma, Italy
Azienda Ospedaliera - Papa Giovanni XXIII
🇮🇹Bergamo, Italy
U.O.C. di Ematologia 1 e 2 IRCCS AOU San Martino-IST
🇮🇹Genova, Italy
Irccs Ospedale S. Raffaele - Milano - Uo Oncoematologia
🇮🇹Milano, Italy
U.O. Ematologia Clinica - Azienda USL di Pescara
🇮🇹Pescara, Italy
Asst Degli Spedali Civili Di Brescia - Uo Ematologia
🇮🇹Brescia, Italy
Ao Brotzu, Presidio Ospedaliero A. Businco - Cagliari - Sc Ematologia E Ctmo
🇮🇹Cagliari, Italy
Ospedale Niguarda " Ca Granda" - SC Ematologia
🇮🇹Milano, Italy
ULSS N.6 Osp. S. Bortolo
🇮🇹Vicenza, Italy
Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - Ematologia
🇮🇹San Giovanni Rotondo, Italy
UO Ematologia con trapianto-Universita' degli Studi di Bari Aldo Moro
🇮🇹Bari, Italy
Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia
🇮🇹Alessandria, Italy
CTMO - Ematologia - Ospedale "Binaghi"
🇮🇹Cagliari, Italy
Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti
🇮🇹Genova, Italy
Universita' "Sapienza" - Dip Biotecnologie Cellulari - Divisione di Ematologia
🇮🇹Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica
🇮🇹Roma, Italy
Universita' Cattolica del Sacro Cuore - Policlinico A. Gemelli
🇮🇹Roma, Italy